BACKGROUND: Different acid and peptic related gastroduodenal diseases are associated with both increased gastric secretion and Helicobacter pylori infection. Patients with H pylori associated gastritis or duodenal ulcer have increased serum pepsinogen levels which decrease after eradication. The mechanisms of H pylori induced gastric mucosal damage are not completely understood. AIM: To determine the effects of H pylori on pepsinogen secretion from isolated human peptic cells. METHODS: Dispersed human peptic cells were prepared from endoscopically obtained biopsy specimens after collagenase digestion, mechanical disruption, and density gradient centrifugation. H pylori was obtained from gastric biopsies (antrum and body), and cultured in non-selective and selective media. Isolates of H pylori were used at different concentrations (1 - 20 x 10(6) colony forming units (cfu)). RESULTS: H pylori (10(6) - 2 x 10(7) cfu) increased basal pepsinogen secretion in a concentration dependent manner. This stimulus was not observed with Escherichia coli. The increased secretion was in addition to that observed with 0.1 mM histamine and 0.1 mM dibutyryl-cyclic adenosine monophosphate. However, H pylori did not affect either carbamylcholine (0.1-10 microM) or cholecystokinin (1 microM) stimulated pepsinogen secretion. Addition of the nitric oxide synthase inhibitor N(w)-monomethyl-L-arginine (1 mM) inhibited H pylori induced cGMP generation and pepsinogen secretion, which were also reduced in the absence of extracellular calcium. H pylori induced pepsinogen secretion was not affected by the absence/presence of the cagA gene. CONCLUSIONS: H pylori increases pepsinogen secretion from human peptic cells through a calcium and nitric oxide mediated intracellular pathway. This effect is independent of the H pylori virulent cagA gene, and may be a mechanism of H pylori induced gastric mucosal damage.
BACKGROUND: Different acid and peptic related gastroduodenal diseases are associated with both increased gastric secretion and Helicobacter pylori infection. Patients with H pylori associated gastritis or duodenal ulcer have increased serum pepsinogen levels which decrease after eradication. The mechanisms of H pylori induced gastric mucosal damage are not completely understood. AIM: To determine the effects of H pylori on pepsinogen secretion from isolated human peptic cells. METHODS: Dispersed human peptic cells were prepared from endoscopically obtained biopsy specimens after collagenase digestion, mechanical disruption, and density gradient centrifugation. H pylori was obtained from gastric biopsies (antrum and body), and cultured in non-selective and selective media. Isolates of H pylori were used at different concentrations (1 - 20 x 10(6) colony forming units (cfu)). RESULTS: H pylori (10(6) - 2 x 10(7) cfu) increased basal pepsinogen secretion in a concentration dependent manner. This stimulus was not observed with Escherichia coli. The increased secretion was in addition to that observed with 0.1 mM histamine and 0.1 mM dibutyryl-cyclic adenosine monophosphate. However, H pylori did not affect either carbamylcholine (0.1-10 microM) or cholecystokinin (1 microM) stimulated pepsinogen secretion. Addition of the nitric oxide synthase inhibitor N(w)-monomethyl-L-arginine (1 mM) inhibited H pylori induced cGMP generation and pepsinogen secretion, which were also reduced in the absence of extracellular calcium. H pylori induced pepsinogen secretion was not affected by the absence/presence of the cagA gene. CONCLUSIONS: H pylori increases pepsinogen secretion from human peptic cells through a calcium and nitric oxide mediated intracellular pathway. This effect is independent of the H pylori virulent cagA gene, and may be a mechanism of H pylori induced gastric mucosal damage.
Authors: B J Marshall; C S Goodwin; J R Warren; R Murray; E D Blincow; S J Blackbourn; M Phillips; T E Waters; C R Sanderson Journal: Lancet Date: 1988 Dec 24-31 Impact factor: 79.321
Authors: G O Young; N Stemmet; A Lastovica; E L van der Merwe; J A Louw; I M Modlin; I N Marks Journal: Aliment Pharmacol Ther Date: 1992-04 Impact factor: 8.171
Authors: J G Coghlan; D Gilligan; H Humphries; D McKenna; C Dooley; E Sweeney; C Keane; C O'Morain Journal: Lancet Date: 1987-11-14 Impact factor: 79.321
Authors: Francesco Di Mario; Lucas Giovanni Cavallaro; Ali Mahamat Moussa; Pietro Caruana; Roberta Merli; Andrea Maini; Simone Bertolini; Nadia Dal Bó; Massimo Rugge; Giulia Martina Cavestro; Giovanni Aragona; Mario Plebani; Angelo Franzé; Giorgio Nervi Journal: Dig Dis Sci Date: 2006-10 Impact factor: 3.199
Authors: L T Nguyen; T Uchida; Y Tsukamoto; T D Trinh; L Ta; H B Mai; H S Le; D Q D Ho; H H Hoang; T Matsuhisa; T Okimoto; M Kodama; K Murakami; T Fujioka; Y Yamaoka; M Moriyama Journal: Eur J Clin Microbiol Infect Dis Date: 2010-04-07 Impact factor: 3.267
Authors: Ho June Song; Se Jin Jang; Sung-Cheol Yun; Young Soo Park; Mi-Jung Kim; Sun-Mi Lee; Kee Don Choi; Gin Hyug Lee; Hwoon-Yong Jung; Jin-Ho Kim Journal: Gut Liver Date: 2010-12-17 Impact factor: 4.519